JP2006512419A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006512419A5 JP2006512419A5 JP2005509731A JP2005509731A JP2006512419A5 JP 2006512419 A5 JP2006512419 A5 JP 2006512419A5 JP 2005509731 A JP2005509731 A JP 2005509731A JP 2005509731 A JP2005509731 A JP 2005509731A JP 2006512419 A5 JP2006512419 A5 JP 2006512419A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- gmcsf
- pharmaceutical composition
- gcsf
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000926 neurological Effects 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 101700003485 CSF2 Proteins 0.000 claims 6
- 102100006400 CSF2 Human genes 0.000 claims 6
- 101700003315 CSF3 Proteins 0.000 claims 6
- 102100006435 CSF3 Human genes 0.000 claims 6
- 210000001178 Neural Stem Cells Anatomy 0.000 claims 6
- 230000001058 adult Effects 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 230000003394 haemopoietic Effects 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 201000006474 brain ischemia Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229920000023 polynucleotide Polymers 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 claims 1
- 206010007515 Cardiac arrest Diseases 0.000 claims 1
- 206010008118 Cerebral infarction Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 1
- 102000003978 Tissue plasminogen activator Human genes 0.000 claims 1
- 108090000373 Tissue plasminogen activator Proteins 0.000 claims 1
- 208000005765 Traumatic Brain Injury Diseases 0.000 claims 1
- 230000002424 anti-apoptotic Effects 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 108010053292 macrophage stimulating protein Proteins 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 1
- 230000003612 virological Effects 0.000 claims 1
Claims (15)
- 哺乳動物における成体神経幹細胞の刺激用の医薬組成物の調製のための、ＧＭＣＳＦ、ＧＭＣＳＦ誘導体、ＧＣＳＦ、ＧＣＳＦ誘導体およびこれらの組み合わせからなる群より選択される造血因子の使用。
- 前記医薬組成物が、神経状態を患う哺乳動物を処置するよう設計される、請求項１に記載の使用。
- 前記神経状態が脳梗塞である、請求項２に記載の使用。
- 前記神経状態がパーキンソン病である、請求項２に記載の使用。
- 前記神経状態が脊髄外傷のような神経外傷である、請求項２に記載の使用。
- 前記神経状態が筋萎縮性側索硬化症である、請求項２に記載の使用。
- 前記神経状態が、脳外傷のような神経外傷、痴呆、多発性硬化症、うつ、心臓停止による脳虚血、または手術の間の脳虚血からなる群より選択される、請求項２に記載の使用。
- 前記医薬組成物が、マクロファージ刺激因子、インターロイキンおよびエリスロポエチンからなる群より選択される、さらなる造血因子を含む、請求項１〜７のいずれかに記載の使用。
- 前記医薬組成物が、さらに、組織プラスミノーゲン活性剤、血液脳関門の通過を促進する薬剤、および抗アポトーシス剤からなる群から選択される物質を含む、請求項１〜８のいずれかに記載の使用。
- 前記造血因子が、ヒト因子であるか、またはヒト因子由来である、請求項１〜９のいずれかに記載の使用。
- 哺乳動物がヒトである、請求項１〜１０のいずれかに記載の使用。
- 哺乳動物における成体神経幹細胞の刺激用の医薬組成物の調製のための、ＧＭＣＳＦ、ＧＭＣＳＦ誘導体、ＧＣＳＦ、ＧＣＳＦ誘導体およびこれらの組み合わせからなる群より選択される造血因子をコードしているポリヌクレオチドの使用。
- 前記ポリヌクレオチドを、ウイルスベクターまたはリポソームによって運搬する、請求項１２に記載の使用。
- 哺乳動物における神経状態の処置のための医薬組成物の調製のための成体神経幹細胞の刺激用の、ＧＭＣＳＦ、ＧＭＣＳＦ誘導体、ＧＣＳＦ、ＧＣＳＦ誘導体およびこれらの組み合わせからなる群より選択される造血因子とインビトロで接触される成体神経幹細胞の使用。
- 前記成体神経幹細胞が、ヒト成人神経幹細胞である、請求項１４に記載の使用。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33175502A | 2002-12-31 | 2002-12-31 | |
| US10/331,755 | 2002-12-31 | ||
| US10/659,295 US7785601B2 (en) | 2002-12-31 | 2003-09-11 | Methods of treating neurological conditions with hematopoietic growth factors |
| US10/659,295 | 2003-09-11 | ||
| PCT/IB2003/006446 WO2004058287A2 (en) | 2002-12-31 | 2003-12-31 | Methods of treating neurological conditions with hematopoeitic growth factors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010199712A Division JP2010270158A (ja) | 2002-12-31 | 2010-09-07 | Ｇｃｓｆまたはｇｃｓｆをコードするヌクレオチドの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006512419A JP2006512419A (ja) | 2006-04-13 |
| JP2006512419A5 true JP2006512419A5 (ja) | 2008-02-21 |
| JP4733521B2 JP4733521B2 (ja) | 2011-07-27 |
Family
ID=32710846
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005509731A Expired - Fee Related JP4733521B2 (ja) | 2002-12-31 | 2003-12-31 | 造血成長因子での、神経状態を処置する方法 |
| JP2010199712A Pending JP2010270158A (ja) | 2002-12-31 | 2010-09-07 | Ｇｃｓｆまたはｇｃｓｆをコードするヌクレオチドの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010199712A Pending JP2010270158A (ja) | 2002-12-31 | 2010-09-07 | Ｇｃｓｆまたはｇｃｓｆをコードするヌクレオチドの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (8) | US7785601B2 (ja) |
| EP (2) | EP2186525A3 (ja) |
| JP (2) | JP4733521B2 (ja) |
| CN (3) | CN100558397C (ja) |
| AT (1) | ATE450268T1 (ja) |
| AU (1) | AU2009201467A1 (ja) |
| DE (1) | DE60330390D1 (ja) |
| RU (1) | RU2008146718A (ja) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1019082B2 (en) * | 1997-10-02 | 2008-06-04 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| CA2492542A1 (en) * | 2002-07-30 | 2004-02-05 | Stem Cell Therapeutics Inc. | Oligodendrocyte production from multipotent neural stem cells |
| US7785601B2 (en) * | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| US7695723B2 (en) * | 2002-12-31 | 2010-04-13 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| WO2004058287A2 (en) * | 2002-12-31 | 2004-07-15 | Axaron Bioscience Ag | Methods of treating neurological conditions with hematopoeitic growth factors |
| WO2004106369A2 (en) | 2003-06-02 | 2004-12-09 | Evolutec Limited | Complement inhibitors from ticks |
| CA2586365A1 (en) * | 2004-11-05 | 2006-05-26 | Northwestern University | Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders |
| US20060257943A1 (en) * | 2005-01-25 | 2006-11-16 | Cis Biotech, Inc. | Ischemic biomarkers and their use to predict adverse neurological events from surgery |
| WO2007019522A2 (en) * | 2005-08-04 | 2007-02-15 | Carlos Lopez | Reversal of adult onset disorders with granulocyte-colony stimulating factors |
| BRPI0614851A2 (pt) * | 2005-08-19 | 2011-04-19 | Commw Scient Ind Res Org | luciferases de arachnocampa |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| US9770485B2 (en) * | 2006-02-21 | 2017-09-26 | Academia Sinica | Methods for rescuing learning and/or memory deficits caused by alzheimer's disease by G-CSF |
| US20070196279A1 (en) * | 2006-02-21 | 2007-08-23 | Shen Che-Kun J | Methods for treating progressive neurodegenerative disorders |
| WO2007105305A1 (ja) * | 2006-03-14 | 2007-09-20 | Japan Tobacco Inc. | 新規なβ－ガラクトシド－α２，６－シアル酸転移酵素、それをコードする遺伝子およびその製造方法 |
| JP5153114B2 (ja) * | 2006-10-12 | 2013-02-27 | 知宏 千葉 | 新規のアルツハイマー病検出方法 |
| KR100812274B1 (ko) * | 2006-10-30 | 2008-03-13 | 한양대학교 산학협력단 | Ｇ-ｃｓｆ를 유효성분으로 하는 당뇨성 말초신경병 예방 및치료제 |
| US20100266528A1 (en) * | 2006-11-17 | 2010-10-21 | Biogen Idec Ma Inc. | Systemic Administration of Colony Stimulating Factors to Treat Amyloid Associated Disorders |
| CN101573447A (zh) * | 2006-12-29 | 2009-11-04 | 赢创德固赛有限责任公司 | 具有降低的产物抑制作用的甲硫氨酸合酶 |
| US7618938B2 (en) * | 2007-02-07 | 2009-11-17 | Academia Sinica | Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly |
| US7723302B2 (en) * | 2007-05-01 | 2010-05-25 | Florida Atlantic University | Method of treating Parkinson's disease |
| JP4927774B2 (ja) * | 2007-10-12 | 2012-05-09 | サントリーホールディングス株式会社 | Ｕｄｐ−グルクロン酸転移酵素およびそれをコードするポリヌクレオチド |
| WO2009055454A2 (en) * | 2007-10-22 | 2009-04-30 | University Of Florida Research Foundation, Inc. | Xylan-utilization regulon for efficient bioprocessing of hemicellulose and uses thereof |
| TW200948964A (en) * | 2008-04-17 | 2009-12-01 | Novozymes As | Laccase variants |
| US9132168B2 (en) * | 2008-08-05 | 2015-09-15 | University Of South Florida | Methods of treating cognitive impairment |
| CA2733126A1 (en) * | 2008-08-05 | 2010-02-11 | University Of South Florida | Methods of treating cognitive impairment |
| CA2736230C (en) * | 2008-09-04 | 2021-06-29 | Abt Holding Company | Use of stem cells to prevent neuronal dieback |
| US9057051B2 (en) | 2008-10-31 | 2015-06-16 | Katholieke Universiteit Leuven | Optimized methods for differentiation of cells into cells with hepatocyte progenitor phenotypes, cells produced by the methods, and methods of using the cells |
| CN102316891A (zh) * | 2009-02-17 | 2012-01-11 | 森格尼斯生物科学有限两合公司 | G-csf用于延长卒中溶栓治疗的治疗时间窗的用途 |
| WO2011011500A1 (en) * | 2009-07-21 | 2011-01-27 | Abt Holding Company | Use of stem cells to reduce leukocyte extravasation |
| US20110020292A1 (en) * | 2009-07-21 | 2011-01-27 | Abt Holding Company | Use of Stem Cells to Reduce Leukocyte Extravasation |
| US9494605B2 (en) | 2009-11-20 | 2016-11-15 | Pharnext | Diagnostic tools for charcot-marie-tooth disease |
| US8652813B2 (en) * | 2009-11-25 | 2014-02-18 | Codexis, Inc. | Recombinant Thermoascus aurantiacus β-glucosidase variants |
| EP2521562B1 (en) | 2010-01-08 | 2019-09-18 | Volution Immuno Pharmaceuticals SA | Ev576 for use in the treatment of viral infections of the respiratory tract |
| WO2017120461A1 (en) | 2016-01-08 | 2017-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
| US9795652B2 (en) * | 2010-02-25 | 2017-10-24 | University Of South Florida | Use of endogenous antioxidant proteins in the treatment of stroke |
| CN102260343A (zh) | 2010-05-25 | 2011-11-30 | 健能隆医药技术（上海）有限公司 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
| WO2011158125A2 (en) | 2010-06-17 | 2011-12-22 | Katholieke Universiteit Leuven | Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells |
| GB201011589D0 (en) * | 2010-07-09 | 2010-08-25 | Reneuron Ltd | Therapeutic cells |
| US20130261165A1 (en) * | 2010-12-16 | 2013-10-03 | The Mclean Hospital Corporation | Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| CN102212542B (zh) * | 2011-04-11 | 2012-12-19 | 上海赛伦生物技术有限公司 | 重组马gmcsf的制备方法及相关马gmcsf核苷酸序列 |
| PL2734634T3 (pl) * | 2011-07-22 | 2020-03-31 | The University Of Chicago | Igf-1 do zastosowania do leczenia migreny |
| EP2737905B1 (en) | 2011-07-25 | 2019-09-11 | Generon (Shanghai) Corporation Ltd. | Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases |
| WO2013036526A1 (en) * | 2011-09-06 | 2013-03-14 | Novozymes A/S | Glucoamylase variants and polynucleotides encoding same |
| WO2013067096A2 (en) * | 2011-11-01 | 2013-05-10 | Metselex, Inc. | Prevention or attenuation of neuropathic pain and kidney injury by tauroursodeoxycholic acid |
| US8889630B2 (en) | 2011-12-23 | 2014-11-18 | Carlos Lopez | Method for hair regrowth using Granulocyte-Colony Stimulating Factor |
| WO2013149064A1 (en) * | 2012-03-30 | 2013-10-03 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells |
| CN113559281A (zh) * | 2012-07-19 | 2021-10-29 | 宾夕法尼亚州研究基金会 | 再生用于在神经系统中治疗疾病和损伤的功能性神经元 |
| CN103193882B (zh) * | 2013-03-29 | 2014-11-05 | 浙江大学 | 胚胎干细胞特异性标志物GM-CSFRα及其应用 |
| SG10201710638UA (en) | 2013-04-12 | 2018-01-30 | Saverio Lafrancesca | Improving organs for transplantation |
| US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
| NZ720949A (en) | 2013-12-09 | 2019-03-29 | Univ Leland Stanford Junior | Methods and compositions for treating aging-associated conditions |
| WO2015185602A1 (en) * | 2014-06-04 | 2015-12-10 | Affiris Ag | Treatment and prevention of parkinson's disease (pd) |
| US10039808B2 (en) * | 2014-10-22 | 2018-08-07 | Michael Chez | Method of treating or improving neurological function in a human subject |
| US9925244B1 (en) | 2015-02-17 | 2018-03-27 | Michael Chez | Treatment of warts in non-immunosuppressed patients |
| CN107921085B (zh) | 2015-06-15 | 2021-10-22 | 小利兰·斯坦福大学托管委员会 | 用于治疗衰老相关病症的方法和组合物 |
| EP4353320A3 (en) | 2016-04-28 | 2024-05-15 | Alkahest, Inc. | Blood plasma and plasma fractions as therapy for tumor growth and progression |
| US10525107B2 (en) | 2016-08-18 | 2020-01-07 | Alkahest, Inc. | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| IL305904A (en) | 2017-04-26 | 2023-11-01 | Alkahest Inc | Dosage regimen for the treatment of cognitive and motor impairments using blood plasma and blood plasma products |
| CN108404118A (zh) * | 2017-06-14 | 2018-08-17 | 张建宁 | 人源乳凝集素亚型蛋白的新用途 |
| US10863912B2 (en) | 2017-08-24 | 2020-12-15 | Myneurva Holdings, Inc. | System and method for analyzing electroencephalogram signals |
| CN111565736B (zh) | 2017-10-11 | 2024-03-08 | 礼蓝美国股份有限公司 | 猪g-csf变体和其用途 |
| WO2019173361A2 (en) | 2018-03-05 | 2019-09-12 | The Schepens Eye Research Institute, Inc. | A therapy for glaucoma and optic neuropathy by targeting colony stimulating factors |
| BR112021006743A2 (pt) | 2018-10-26 | 2021-07-13 | Alkahest, Inc. | uso de plasma e frações plasmáticas para melhoria de dor, cicatrização de ferida e recuperação pós-operatória |
| WO2023154855A2 (en) * | 2022-02-11 | 2023-08-17 | Partner Therapeutics, Inc. | Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004548A (en) | 1985-08-23 | 1999-12-21 | Amgen, Inc. | Analogs of pluripotent granulocyte colony-stimulating factor |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5641663A (en) | 1985-11-06 | 1997-06-24 | Cangene Corporation | Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces |
| ES2036530T3 (es) * | 1986-01-22 | 1993-06-01 | Chugai Seiyaku Kabushiki Kaisha | Utilizacion de un factor estimulante de las colonias granulociticas humano para preparar una composicion farmaceutica para el tratamiento de la leucemia mielogena. |
| DK203187A (da) | 1986-04-22 | 1987-10-23 | Immunex Corp | Human g-csf proteinekspression |
| WO1988002482A1 (en) | 1986-09-30 | 1988-04-07 | Obrien Richard Wyndham | Determination of particle size and electric charge |
| NO176799C (no) | 1986-12-23 | 1995-05-31 | Kyowa Hakko Kogyo Kk | DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid |
| US5214132A (en) | 1986-12-23 | 1993-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| GB2213821B (en) | 1987-12-23 | 1992-01-02 | British Bio Technology | Synthetic human granulocyte colony stimulating factor gene |
| US5599690A (en) | 1988-02-01 | 1997-02-04 | Amgen Inc. | Control of norleucine incorporation into recombinant proteins |
| US5021239A (en) | 1988-03-21 | 1991-06-04 | Genetics Institute, Inc. | Use of M-CSF to improve lipoprotein cholesterol profiles |
| CA1340810C (en) | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
| ES2063783T3 (es) | 1988-06-03 | 1995-01-16 | Chugai Pharmaceutical Co Ltd | Factor de cristalino humano de estimulacion de colonias de granulocitos y procedimiento para su preparacion. |
| US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5629283A (en) | 1989-08-11 | 1997-05-13 | Amrad Corporation Limited | Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof |
| EP0439952A3 (en) | 1990-01-31 | 1992-09-09 | Sgs-Thomson Microelectronics, Inc. | Dual-port cache tag memory |
| US5492534A (en) | 1990-04-02 | 1996-02-20 | Pharmetrix Corporation | Controlled release portable pump |
| GB9107846D0 (en) | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
| DE4014750A1 (de) | 1990-05-08 | 1991-11-14 | Boehringer Mannheim Gmbh | Muteine des granulozyten-stimulierenden faktors (g-csf) |
| JP2946231B2 (ja) | 1990-05-31 | 1999-09-06 | 株式会社栗本鐵工所 | 超微粉分級機 |
| JPH04198134A (ja) | 1990-11-28 | 1992-07-17 | Eisai Co Ltd | 老人性痴呆症の治療・予防剤 |
| DE4105480A1 (de) | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
| JP3537151B2 (ja) | 1991-12-26 | 2004-06-14 | 中外製薬株式会社 | 脳機能障害による疾患の予防・治療薬 |
| US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| WO1994028919A1 (en) * | 1993-06-08 | 1994-12-22 | Ajinomoto Co., Inc. | Hematopoietic cell proliferation accelerator |
| US6465616B1 (en) * | 1994-04-08 | 2002-10-15 | Bresagen Limited | Interleukin-5 antagonist |
| US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
| US5474552A (en) | 1994-06-27 | 1995-12-12 | Cb-Carmel Biotechnology Ltd. | Implantable drug delivery pump |
| DE19518505A1 (de) | 1995-05-19 | 1996-11-21 | Max Planck Gesellschaft | Verfahren zur Genexpressionsanalyse |
| US5995860A (en) | 1995-07-06 | 1999-11-30 | Thomas Jefferson University | Implantable sensor and system for measurement and control of blood constituent levels |
| US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
| CA2213906A1 (en) * | 1996-09-23 | 1998-03-23 | Dusica Maysinger | Pharmaceutical composition and method for neuron rescue in ischemic stroke |
| JPH10158188A (ja) * | 1996-11-29 | 1998-06-16 | Senju Pharmaceut Co Ltd | 角膜治療用組成物 |
| US5895647A (en) * | 1996-12-20 | 1999-04-20 | The United States Of America As Represented By The Secretary Of The Navy | Use of oral interleukin-6 as therapy for hemorrhagic shock |
| JP3503418B2 (ja) | 1997-05-15 | 2004-03-08 | ミノルタ株式会社 | 誘導加熱定着装置 |
| US20010049381A1 (en) * | 1997-06-04 | 2001-12-06 | Gpl Nil Holdings, Inc., | Pyrrolidine derivative hair growth compositions and uses |
| US6093167A (en) | 1997-06-16 | 2000-07-25 | Medtronic, Inc. | System for pancreatic stimulation and glucose measurement |
| EP1019082B2 (en) | 1997-10-02 | 2008-06-04 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| CA2323638A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
| EP1080093A4 (en) | 1998-05-22 | 2002-10-28 | Smithkline Beecham Corp | G-CSF mimetics |
| WO1999061446A1 (en) | 1998-05-22 | 1999-12-02 | Smithkline Beecham Corporation | G-csf mimetics |
| US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| DE69910216T2 (de) | 1998-07-22 | 2004-02-19 | Osprey Pharmaceuticals Ltd., Calgary | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung |
| US6554798B1 (en) | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
| US6261250B1 (en) | 1998-08-20 | 2001-07-17 | Rle Corporation | Method and apparatus for enhancing cardiovascular activity and health through rhythmic limb elevation |
| US6610540B1 (en) | 1998-11-18 | 2003-08-26 | California Institute Of Technology | Low oxygen culturing of central nervous system progenitor cells |
| HU228488B1 (en) | 1999-01-29 | 2013-03-28 | Amgen Inc | Gcsf conjugates |
| JP2004500058A (ja) * | 1999-12-03 | 2004-01-08 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | サイトカインレセプター様ポリヌクレオチド、ポリペプチド、および抗体 |
| DE10033219A1 (de) | 2000-07-07 | 2002-01-24 | Univ Heidelberg | Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF) |
| IL154609A0 (en) * | 2000-09-01 | 2003-09-17 | Bioacta Ltd | Anti-angiogenic polypeptides |
| ATE348883T1 (de) | 2000-09-08 | 2007-01-15 | Massachusetts Inst Technology | Zusammensetzungen und verfahren mit analogen von g-csf |
| WO2002022163A1 (fr) | 2000-09-13 | 2002-03-21 | Chugai Seiyaku Kabushiki Kaisha | Remedes contre des maladies ischemiques |
| AU2002219830A1 (en) * | 2000-11-10 | 2002-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating disorders of neuronal deficiency with bone marrow-derived cells |
| JP3607271B2 (ja) | 2001-03-12 | 2005-01-05 | 株式会社Ｇｂｓ研究所 | 神経損傷の治療薬 |
| JP3763749B2 (ja) | 2001-03-28 | 2006-04-05 | 独立行政法人科学技術振興機構 | 脊髄におけるシナプス形成ニューロンを誘導する中枢神経系前駆細胞 |
| AU2002316201A1 (en) * | 2001-06-07 | 2002-12-16 | Quark Biotech, Inc. | Methods of using colony stimulating factors in the treatment of tissue damage and ischemia |
| FR2834898B1 (fr) | 2002-01-18 | 2005-06-10 | Didier Pourquier | Nouvelle application therapeutique du g-csf, du gm-csf et du scf |
| DE10211063A1 (de) | 2002-03-13 | 2003-10-09 | Axaron Bioscience Ag | Neue Verfahren zur Detektion und Analyse von Protein-Interaktionen in vivo |
| AU2003240614A1 (en) | 2002-05-10 | 2003-11-11 | Ipf Pharmaceuticals Gmbh | A method of inhibiting the emigration of cells from the intravascular compartment into tissues |
| EP2105136A3 (en) * | 2002-05-17 | 2010-01-27 | Celgene Corporation | Pharmaceutical compositions for treating cancer |
| CA2486141A1 (en) * | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| CA2492542A1 (en) | 2002-07-30 | 2004-02-05 | Stem Cell Therapeutics Inc. | Oligodendrocyte production from multipotent neural stem cells |
| AU2003286611A1 (en) * | 2002-10-24 | 2004-05-13 | Sangstat Medical Corporation | Cytomodulating peptides and methods for treating neurological disorders |
| US7695723B2 (en) | 2002-12-31 | 2010-04-13 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| JP4198134B2 (ja) | 2005-04-13 | 2008-12-17 | 京セラミタ株式会社 | 給紙装置 |
| EP2036571A1 (de) * | 2007-09-13 | 2009-03-18 | Sygnis Bioscience GmbH & Co. KG | Verwendung von G-CSF für die Behandlung von Schlaganfall |
-
2003
- 2003-09-11 US US10/659,295 patent/US7785601B2/en not_active Expired - Fee Related
- 2003-12-31 CN CNB2003801100755A patent/CN100558397C/zh not_active Expired - Fee Related
- 2003-12-31 CN CN2009101755154A patent/CN101926981A/zh active Pending
- 2003-12-31 CN CN200910175516A patent/CN101693107A/zh active Pending
- 2003-12-31 EP EP09011942A patent/EP2186525A3/en not_active Withdrawn
- 2003-12-31 DE DE60330390T patent/DE60330390D1/de not_active Expired - Lifetime
- 2003-12-31 JP JP2005509731A patent/JP4733521B2/ja not_active Expired - Fee Related
- 2003-12-31 AT AT03799727T patent/ATE450268T1/de not_active IP Right Cessation
- 2003-12-31 EP EP10011006A patent/EP2311483A1/en not_active Withdrawn
-
2007
- 2007-08-29 US US11/846,699 patent/US20080279814A1/en not_active Abandoned
- 2007-10-31 US US11/930,758 patent/US7884069B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/932,383 patent/US8053407B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/931,295 patent/US8071543B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/931,618 patent/US20080181865A1/en not_active Abandoned
- 2007-10-31 US US11/931,326 patent/US20080171080A1/en not_active Abandoned
-
2008
- 2008-11-26 RU RU2008146718/15A patent/RU2008146718A/ru not_active Application Discontinuation
-
2009
- 2009-04-07 AU AU2009201467A patent/AU2009201467A1/en not_active Abandoned
-
2010
- 2010-09-07 JP JP2010199712A patent/JP2010270158A/ja active Pending
-
2012
- 2012-02-02 US US13/364,381 patent/US20120231065A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006512419A5 (ja) | ||
| WO2005000245A3 (en) | Compositions and methods for increasing telomerase activity | |
| Dai et al. | Transplantation of autologous bone marrow mesenchymal stem cells in the treatment of complete and chronic cervical spinal cord injury | |
| Zhang et al. | The dose–effect relationship in extracorporeal shock wave therapy: The optimal parameter for extracorporeal shock wave therapy | |
| WO2005044179A3 (en) | Formulations containing astragalus extracts and uses thereof | |
| WO2010057112A3 (en) | Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets | |
| GEP20094781B (en) | Sulfonamide derivatives for the treatment of diseases | |
| IL172613A (en) | Antibodies that bind at least two different human inhibitory kir gene products, hybridomas producing said antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies and use thereof for the manufacture of a medicament to potentiate nk cell activity | |
| CA2518219A1 (en) | Igf-binding protein-derived peptide or small molecule | |
| EP3818991A3 (en) | Compositions and methods for treating diseases | |
| WO2006078782A3 (en) | Compositions containing agm cells and methods of use thereof | |
| Andrews | Amyotrophic lateral sclerosis: clinical management and research update | |
| SG11201900986YA (en) | Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells | |
| CA2348882A1 (en) | Pharmaceutical composition comprising a combination of dextro- and laevo- isomers of sotalol | |
| Crevits | Brachioradial pruritus—a peculiar neuropathic disorder | |
| Feng et al. | Stromal cell-derived factor 1 protects human periodontal ligament stem cells against hydrogen peroxide-induced apoptosis | |
| TW200740440A (en) | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | |
| WO2006119965A3 (en) | Growth factor mutants with altered biological attributes | |
| WO2005011573A3 (en) | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | |
| EP1059931B1 (de) | Verwendung von cd137 zur förderung der proliferation peripherer monocyten | |
| CN107050060A (zh) | 治疗牛皮癣的外用药及药物组合物 | |
| JP2014501242A5 (ja) | ||
| RU2338513C1 (ru) | Средство для фиксации съемных зубных протезов | |
| Shalev et al. | Symptomatic Brugada unmasked by fever | |
| EP2198861A3 (en) | eNOS transcription enhancers for use in the cell therapy of ischemic heart diseases |